Danaher Corporation (NYSE:DHR) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

Danaher Corporation (NYSE:DHR) Files An 8-K Results of Operations and Financial Condition

ITEM2.02

RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On January10, 2017, in advance of a publicly webcast presentation
at the J.P. Morgan Healthcare Conference on January10, 2017,
Danaher Corporation (Danaher or the Company) furnished to
Item2.02 of Form 8-K the presentation slides attached hereto,
which are incorporated by reference herein. The presentation
slides attached hereto contain certain information regarding
Danahers anticipated financial performance for 2016.

Following is required reconciliation and other information
relating to the non-GAAP measures included in the attached
presentation slides:

$ in Billions
Year Ended December31,2016 (estimated)


Estimated Free Cash Flow from Continuing
Operations:


Estimated Operating Cash Flows from Continuing Operations
(GAAP)

$ 3.1


Less: estimated purchases of property, plant equipment
(capital expenditures) from continuing operations (GAAP)

(0.6 )


Estimated Free Cash Flow from Continuing Operations
(Non-GAAP)

$ 2.5


Ratio of Free Cash Flow to Net Earnings:


Estimated Free Cash Flow from Continuing Operations from
Above (Non-GAAP)

$ 2.5


Estimated Net Earnings from Continuing Operations (GAAP)

2.1


Estimated Free Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Conversion Ratio
(Non-GAAP)

~120 %

Free cash flow should be considered in addition to, and not as a
replacement for or superior to, operating cash flow, and may not
be comparable to similarly titled measures reported by other
companies. Management believes that free cash flow provides
useful information to investors by offering additional ways of
viewing Danahers results that, when reconciled to operating cash
flow, helps our investors to understand Danahers ability to
generate cash without external financings, strengthen its balance
sheet, invest in its business and grow its business through
acquisitions and other strategic opportunities (although a
limitation of operating cash flow is that it does not take into
account the Companys debt service requirements and other
non-discretionary expenditures).

This information shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in
such a filing.


ITEM9.01 		FINANCIAL STATEMENTS AND EXHIBITS


(c) 		Exhibits:


ExhibitNo.


Description


99.1

Selected Danaher Presentation Slides for J. P. Morgan
Healthcare Conference on January 10, 2017


About Danaher Corporation (NYSE:DHR)

Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates in five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental, and Industrial Technologies. Its Test & Measurement segment offers products, software and services. Its Environmental segment products and services help protect the water supply, enhance the safety of personal data and improve business efficiencies. In the Life Sciences & Diagnostics segment, its diagnostics business offers analytical instruments, reagents, consumables, software and services. Its life sciences business offers research tools. Its Dental segment provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. Its Industrial Technologies segment solutions help protect the world’s food supply, improve packaging design and quality, and verify pharmaceutical dosages.

Danaher Corporation (NYSE:DHR) Recent Trading Information

Danaher Corporation (NYSE:DHR) closed its last trading session 00.00 at 80.59 with 2,317,422 shares trading hands.